Jain M, Vargese J, Venkatatraman J. Tenofovir induced severe thrombocytopenia. World J Pharmacology 2017; 6(2): 11-13 [DOI: 10.5497/wjp.v6.i2.11]
Corresponding Author of This Article
Dr. Mayank Jain, Institute of Liver Disease and Transplantation, Gleneagles Global Health City, Perumbakkam, Chennai 600100, India. mayank4670@rediffmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Pharmacology. Jun 9, 2017; 6(2): 11-13 Published online Jun 9, 2017. doi: 10.5497/wjp.v6.i2.11
Tenofovir induced severe thrombocytopenia
Mayank Jain, Joy Vargese, Jayanthi Venkatatraman
Mayank Jain, Joy Vargese, Jayanthi Venkatatraman, Institute of Liver Disease and Transplantation, Gleneagles Global Health City, Chennai 600100, India
Author contributions: All authors contributed to the acquisition of data, writing, and revision of this manuscript.
Institutional review board statement: As per institutional policy, we are not required to take Ethical Committee clearance for case reports.
Informed consent statement: As the patient has already given consent for reporting (attached), ethical clearance is not needed. No reports/images disclosing the patient identity have been used in the submission.
Conflict-of-interest statement: The authors do not report any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Mayank Jain, Institute of Liver Disease and Transplantation, Gleneagles Global Health City, Perumbakkam, Chennai 600100, India. mayank4670@rediffmail.com
Telephone: +91-44-24242424 Fax: +91-44-22777100
Received: February 13, 2017 Peer-review started: February 15, 2017 First decision: March 7, 2017 Revised: March 15, 2017 Accepted: April 16, 2017 Article in press: April 17, 2017 Published online: June 9, 2017 Processing time: 102 Days and 7.4 Hours
Abstract
Tenofovir disoproxil fumarate is used in the management of hepatitis B and human immunodeficiency virus infection. We present a 50 years old lady, post liver transplant, who was switched over from entecavir to tenofovir, for management of hepatitis B reactivation. She developed bleeding diathesis and severe thrombocytopenia was detected on investigations. Bone marrow examination showed normocellular marrow with megakaryocytes. Tenofovir was stopped and she was started on intravenous immunoglobulin, followed by steroids. There was improvement in platlet counts. The case highlights a rare side effect of tenofovir therapy.
Core tip: The present case report highlights a rare side effect of tenofovir therapy for hepatitis B infection. As the drug is commonly used in for management of hepatitis B and human immunodeficiency virus infection, the knowledge to this rare side effect would help physicians to be more watchful and improve patient management.
